Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China
CsA provides superior response durability, survival outcomes, and safety compared with other approaches, supporting its use as first-line therapy in lower-risk hMDS. Integration of immune and molecular profiling may refine individualized treatment strategies.
Authors
- Limin Xing (ORCID: https://orcid.org/0000-0002-0182-8892)
- Liyan Yang (ORCID: https://orcid.org/0009-0004-5878-9363)
- Zonghong Shao (ORCID: https://orcid.org/0000-0003-4966-2956)
- Huaquan Wang (ORCID: https://orcid.org/0000-0003-2402-2717)
- Huijuan Jiang (ORCID: https://orcid.org/0000-0001-6002-9102)
- Lijuan Li (ORCID: https://orcid.org/0000-0001-5984-1603)
- Wei Zhang (ORCID: https://orcid.org/0000-0002-6968-6974)
- Rong Fu (ORCID: https://orcid.org/0000-0002-9928-9224)
- Yumei Liu (ORCID: https://orcid.org/0009-0004-5986-4943)
- Yongxiang Wei (ORCID: https://orcid.org/0009-0002-4656-9289)
Institutions
- Tianjin Medical University General Hospital (CN)
- Tianjin People's Hospital (CN)
Publication Details
- Journal
- Hematology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1080/16078454.2025.2605379
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00